Opus Genetics Stock Investor Sentiment
| IRD Stock | 2.77 0.00 0.00% |
About 69 percent of all Opus Genetics' shareholders are curious in acquiring. The analysis of overall sentiment of trading Opus Genetics stock suggests that quite a large number of investors are confidant at this time. The current market sentiment, together with Opus Genetics' historical and current headlines, can help investors time the market. In addition, many technical investors use Opus Genetics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 69
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Opus Genetics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Opus Genetics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
Opus Historical Sentiment
Although Opus Genetics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Opus, such as negative comments on social media and news outlets, may cause fear in the market and push Opus Genetics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Opus.
Opus Genetics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Opus Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Opus Genetics Historical Investor Sentiment
Investor biases related to Opus Genetics' public news can be used to forecast risks associated with an investment in Opus. The trend in average sentiment can be used to explain how an investor holding Opus can time the market purely based on public headlines and social activities around Opus Genetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Opus Genetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Opus Genetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Opus Genetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Opus Genetics.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Opus Genetics' Stock prices. Below is the latest headlines and news related to Opus Genetics Stock. The global stock market is bearish. About 66% of major world exchanges and indexes are down. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Opus Genetics that are available to investors today. This information is accessible both publicly - through Opus Genetics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Opus-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Opus Genetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Opus Genetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Opus Genetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Opus Genetics alpha.
Opus Largest EPS Surprises
Earnings surprises can significantly impact Opus Genetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.25 | -0.2879 | -0.0379 | 15 | ||
2024-08-13 | 2024-06-30 | -0.24 | -0.3 | -0.06 | 25 | ||
2025-08-13 | 2025-06-30 | -0.19 | -0.12 | 0.07 | 36 | ||
2025-11-12 | 2025-09-30 | -0.132 | -0.25 | -0.118 | 89 | ||
2023-05-15 | 2023-03-31 | -0.16 | -0.28 | -0.12 | 75 | ||
2024-03-08 | 2023-12-31 | -0.05 | -0.21 | -0.16 | 320 |
There is far too much social signal, news, headlines, and media speculation about Opus Genetics that are available to investors today. This information is accessible both publicly - through Opus Genetics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Opus-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Opus Genetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Opus Genetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Opus Genetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Opus Genetics alpha.
Opus Genetics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Fortrea Holdings Inc. Q3 Earnings Lag Estimates | 11/05/2025 |
2 | Analysts Offer Insights on Healthcare Companies Opus Genetics , Bristol-Myers Squibb and PACS Group Inc - The Globe and Mail | 11/21/2025 |
3 | Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 12 Trial in Best Disease | 12/09/2025 |
4 | Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | 12/11/2025 |
5 | Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 12/16/2025 |
6 | Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks | 12/19/2025 |
7 | Acquisition by Gallagher Cam of 83000 shares of Opus Genetics at 1.9689 subject to Rule 16b-3 | 12/29/2025 |
8 | Opus Genetics, Inc. Receives Average Rating of Moderate Buy from Analysts - MarketBeat | 12/30/2025 |
9 | Acquisition by Ainsworth Sean of 42507 shares of Opus Genetics at 1.99 subject to Rule 16b-3 | 12/31/2025 |
10 | Opus Genetics Cut to Sell at Wall Street Zen - MarketBeat | 01/02/2026 |
11 | Acquisition by Gallagher Cam of 67000 shares of Opus Genetics subject to Rule 16b-3 | 01/06/2026 |
12 | Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts | 01/08/2026 |
13 | Disposition of 50 shares by Zaremba Rabourn Amy of Opus Genetics at 1.93 subject to Rule 16b-3 | 01/09/2026 |
14 | Disposition of 3390 shares by Zaremba Rabourn Amy of Opus Genetics at 2.1 subject to Rule 16b-3 | 01/16/2026 |
15 | Opus Genetics, Inc. Receives Consensus Rating of Moderate Buy from Analysts - MarketBeat | 01/23/2026 |
Complementary Tools for Opus Stock analysis
When running Opus Genetics' price analysis, check to measure Opus Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics is operating at the current time. Most of Opus Genetics' value examination focuses on studying past and present price action to predict the probability of Opus Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics' price. Additionally, you may evaluate how the addition of Opus Genetics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |